Healthcare - Biotechnology - NASDAQ - US
$ 2.02
-2.88 %
$ 230 M
Market Cap
-1.23
P/E
CASH FLOW STATEMENT
-132 M
OPERATING CASH FLOW
113 M
INVESTING CASH FLOW
85 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Fate Therapeutics, Inc.
| Net Income | -161 M |
| Depreciation & Amortization | 18.3 M |
| Capital Expenditures | -6.15 M |
| Stock-Based Compensation | 43.5 M |
| Change in Working Capital | 19.2 M |
| Others | -40.8 M |
| Free Cash Flow | -138 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||||||||
| Net Income | (160.9) | (281.7) | (212.2) | (173.4) | (98.1) | (66.6) | (43.0) | (33.5) | (30.0) | (25.9) | (20.9) | (14.2) | (13.4) |
| Depreciation & Amortization | 18.3 | 13.8 | 5.8 | 3.1 | 2.2 | 1.2 | 1.0 | 0.9 | 0.7 | 0.5 | 0.6 | 0.6 | 0.7 |
| Deferred Income Tax | 0 | 0 | 5.1 | 1.7 | (0.5) | (0.3) | 5 K | 0.2 | 0 | 3 K | 26 K | 0 | 0.1 |
| Stock Based Compensation | 43.5 | 78.7 | 54.4 | 30.8 | 17.4 | 6.3 | 3.6 | 3.2 | 2.4 | 2.4 | 1.6 | 0.2 | 0.2 |
| Other Operating Activities | (52.3) | (24.3) | (18.1) | 111.4 | (7.8) | 19.0 | (0.6) | (1.6) | 8.1 | 0.5 | 3.1 | 0.2 | 95 K |
| Change in Working Capital | 19.2 | (34.7) | 2.1 | (12.8) | 3.6 | 1.7 | 2.1 | 1.2 | 0.4 | 17 K | 0.3 | 0 | 0.3 |
| Cash From Operations | (132.3) | (248.2) | (162.9) | (39.2) | (83.2) | (38.6) | (36.9) | (29.8) | (18.4) | (22.4) | (15.4) | (13.3) | (12.1) |
| INVESTING CASH FLOW | |||||||||||||
| Capital Expenditures | (6.2) | (35.6) | (50.7) | (4.9) | (7.4) | (2.3) | (1.7) | (0.5) | (1.5) | (0.9) | (0.2) | (0.7) | 2 K |
| Other Items | 118.8 | 202.3 | (273.3) | (156.1) | (150.1) | 1.8 | (8.5) | (3.7) | 0 | 0 | 6 K | 0 | 0.2 |
| Cash From Investing Activities | 112.7 | 166.8 | (324.0) | (161.1) | (157.5) | (0.5) | (10.2) | (4.1) | (1.5) | (0.9) | (0.2) | (0.7) | 0.2 |
| FINANCING CASH FLOW | |||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 K |
| Total Debt Repaid | 0 | 0 | 0 | 0 | (15.0) | 0 | 4.1 | (7.7) | (1.5) | 18.2 | 20.1 | (0.2) | 3.6 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 85 K | 9.2 | 41.4 | 10.1 | 2.5 | 6.2 | 0.2 | 36.6 | 0.4 | 0.1 | 40.5 | 16.7 | 3.5 |
| Cash From Financing Activities | 85 K | 9.2 | 453.1 | 282.8 | 149.9 | 140.8 | 47.4 | 57.7 | 35.6 | 18.4 | 60.6 | 16.7 | 7.1 |
| CHANGE IN CASH | |||||||||||||
| Net Change In Cash | (19.5) | (72.2) | (33.8) | 82.5 | (90.7) | 101.7 | 0.3 | 23.8 | 15.7 | (4.9) | 44.9 | 2.7 | (4.8) |
| FREE CASH FLOW | |||||||||||||
| Free Cash Flow | (138.4) | (283.8) | (213.6) | (44.2) | (90.6) | (41.0) | (38.6) | (30.3) | (19.9) | (23.3) | (15.6) | (14.0) | (12.1) |